Please login to the form below

Not currently logged in
Email:
Password:

US diabetes specialist claims GSK made threats over Avandia

The controversy over GSK diabetes drug, Avandia, has taken another surprise turn, when a medical expert in the US accused the UK's largest pharmaceutical firm of trying to silence him when he questioned the drug's safety

The controversy over GlaxoSmithKline's (GSK) diabetes drug, Avandia (roseglitazone), has taken another surprise turn, when a medical expert in the US accused the UK's largest pharmaceutical firm of trying to silence him when he questioned the drug's safety.

Dr John Buse, who is a diabetes expert from the University of North Carolina, said that he had received telephone calls from GSK executives when the drug went on sale in 1999, claiming his "actions were scurrilous enough to attempt to hold me liable for a loss in market capitalisation".

Buse, who disclosed the threats of legal action in a written testimony submitted for a congressional hearing on the drug's safety on 6 June, said that later he had signed a statement drafted by GSK to ease concerns that his warnings had raised among shareholders.

GSK's CEO, JP Garnier, strongly rejected Buse's claims: "We don't threaten people. Dr Buse did issue a correction. There are no hard feelings."

PMLive reported last week that Buse had written a letter to the FDA warning that the drug might increase the risk of heart attacks. He also criticised GSK's "blatant selective manipulation of data", which he said had "understated the drugs risks and overstated its benefits".

Published research in the New England Journal of Medicine (NEJM), which claimed Avandia caused cardiovascular problems, has prompted the US House of Representatives' Committee on Oversight and Government Reform to convene a hearing into the FDA's role in evaluating the safety of Avandia.

Henry Waxman, the committee's chairman, has criticised FDA Commissioner, Andrew von Eschenbach, for failing to request specific research into Avandia's cardiovascular damage profile after Buse and, later, the World Health Organisation, gave warnings of a potential connection. The FDA has been under increased scrutiny over its drug safety procedures.

7th June 2007

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
claire@dovetailstrategies.com

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics